The information contained in this section of the site is intended for US health care professionals only. Click “OK” if you are a health care professional or specialty pharmacy representative.
The information contained in this section of the site is intended for specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
ACTEMRA Intravenous (IV) and ACTEMRA for self-injection are FDA-approved for use in moderate to severe RA patients that have had an inadequate response to a DMARD and patients with polyarticular juvenile idiopathic arthritis (PJIA). If you are this type of patient, and switching from ACTEMRA IV to ACTEMRA for self-injection, you do not need to reapply for the program. Once you qualify and are enrolled in the program, you are eligible to receive $15,000 per 12-month period, subject to submission of documents required for funding of the card with co-pay assistance payments. Note that ACTEMRA for self-injection is not approved for use in patients with systemic juvenile idiopathic arthritis (SJIA) and ACTEMRA IV is not approved for use in giant cell arteritis (GCA) patients. The ACTEMRA Co-Pay Card Program provides drug co-pay assistance for out-of-pocket costs of ACTEMRA only when ACTEMRA IV or ACTEMRA self-injection is prescribed for an approved use.
If you have any additional questions, please call (855) RA-COPAY (855-722-6729) from 6 a.m.–5 p.m. PT, Monday through Friday, except major holidays.
ACTEMRA is a prescription medicine used to treat:
ACTEMRA is not approved for subcutaneous use in people with SJIA.
It is not known if ACTEMRA is safe and effective in children with PJIA or SJIA under 2 years of age or in children with conditions other than PJIA or SJIA.
ACTEMRA can cause serious side effects
ACTEMRA changes the way your immune system works. This can make you more likely to get infections or make any current infection worse. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with ACTEMRA.
Do not take ACTEMRA if you are allergic to tocilizumab, or any of the ingredients in ACTEMRA.
ACTEMRA can cause other serious side effects. These include:
Tears (perforation) of the Stomach or Intestines
If you have diverticulitis (inflammation in parts of the large intestine), talk to your healthcare provider before taking ACTEMRA. Some people taking ACTEMRA may develop a hole in the wall of their stomach or intestines (also known as a perforation).
Changes in Blood Test Results
Your healthcare provider should do blood tests before you start receiving ACTEMRA. You should not receive ACTEMRA if your neutrophil and platelet counts are too low or your liver function test levels are too high. These may cause your healthcare provider to stop your ACTEMRA treatment for a time or change your dose.
ACTEMRA may increase your risk of certain cancers by changing the way your immune system works.
Hepatitis B Infection
If you have or are a carrier of the hepatitis B virus (a virus that affects the liver), the virus may become active while you use ACTEMRA. Your healthcare provider may do blood tests before you start treatment with ACTEMRA and while you are using ACTEMRA.
Serious Allergic Reactions
Serious allergic reactions, including death, can happen with ACTEMRA. These reactions can happen with any infusion or injection of ACTEMRA, even if they did not occur with an earlier infusion or injection.
Nervous System Problems
While rare, Multiple Sclerosis has been diagnosed in people who take ACTEMRA.
The most common side effects of ACTEMRA include:
ACTEMRA & Pregnancy
Tell your healthcare provider if you are planning to become pregnant, are pregnant, plan to breast-feed, or are breast-feeding. If you are pregnant and taking ACTEMRA, join the pregnancy registry. To learn more, call 1-877-311-8972 or talk to your healthcare provider to register.
Tell your healthcare provider if you have any side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.